<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01345708</url>
  </required_header>
  <id_info>
    <org_study_id>Eudra CT 2008-006713-25</org_study_id>
    <nct_id>NCT01345708</nct_id>
  </id_info>
  <brief_title>A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic Anemia</brief_title>
  <official_title>A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Udine, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this prospective study was to evaluate the activity, safety and the duration of
      the response of low dose rituximab associated with standard oral prednisone as first line
      therapy in newly diagnosed warm autoimmune hemolytic anemia and cold hemagglutinin disease,
      and as second line therapy in warm autoimmune hemolytic anemia relapsed after standard oral
      prednisone. Further aim was to correlate the clinical response to biological parameters
      (cytokine and anti-erythrocyte antibody production in cultures).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response</measure>
    <time_frame>month +2</time_frame>
    <description>Response will be evaluated at each clinic visit. Complete response (CR) will be defined as Hb increase &gt;2 g/dL and Hb &gt; 12 g/dL, normalization of all haemolytic markers and no transfusion requirement;Partial response (PR) will be defined as Hb increase &gt;2 g/dL and Hb 10-12 g/dL, and 50% reduction of transfusion. In the remaining cases there is no response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sustained response (SR)</measure>
    <time_frame>month +6, month +12</time_frame>
    <description>Sustained response (SR) was defined as Hb &gt; 10 g/dL at month +6 and +12, in the absence of any treatment.</description>
  </secondary_outcome>
  <enrollment type="Actual">23</enrollment>
  <condition>Autoimmune Hemolytic Disease (Cold Type) (Warm Type)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone, low dose rituximab</intervention_name>
    <description>Patients with &quot;warm&quot; AIHA will receive:
Rituximab 100 mg i.v.weekly (fixed dose irrespective of body surface area) for 4 consecutive weeks (days +7, +14, +21, +28), and prednisone 1 mg/kg/die p.o. days from day +1 to day +30, followed by tapering (10 mg/week until 0.5/mg/kg/die, then 5 mg/week until stop)
Patients with CHD will receive:
Rituximab 100 mg i.v.weekly (fixed dose irrespective of body surface area) for 4 consecutive weeks (days +7, +14, +21, +28)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed &quot;warm&quot; or &quot;cold&quot; AIHA, defined by symptomatic anemia and positive DAT,
             in the absence of underlying lymphoproliferative, infectious or neoplastic disease
             (according to the single Center diagnostic criteria).

          -  Idiopathic &quot;warm&quot; or &quot;cold&quot; AIHA relapsed after first line treatment with oral
             prednisone.

          -  Aged &gt;18 years

          -  ECOG performance status grade 0, 1 or 2

          -  No psychiatric illness that precludes understanding concepts of the trial or signing
             informed consent

          -  Patients who have provided written informed consent prior to study participation, with
             the understanding that the consent may be withdrawn by the patient at any time without
             prejudice.

        Exclusion Criteria:

          -  Cell or humoral immunologic deficit (congenital or acquired)

          -  Any other co-existing medical or psychological condition that would preclude
             participation in the study or compromise ability to give informed consent

          -  Active bacterial, viral, or fungal infection requiring systemic therapy HIV or HbsAg
             positive (with HBV-DNA+) or HCV-Ab positive (with HCV-RNA+) patients

          -  History of malignancies within 3 years prior to study entry

          -  Concomitant immunosuppressive or cytotoxic treatment

          -  Positive pregnancy test. Lactation.

          -  The presence of associated organ-specific autoimmune diseases do not constitute
             exclusion criteria. Previous splenectomy does not constitute exclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PierMannuccio Mannucci, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via F. Sforza 28 20122, Milano.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>MIlan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilma Barcellini MD, UO Ematologia 2, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Provan D, Butler T, Evangelista ML, Amadori S, Newland AC, Stasi R. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica. 2007 Dec;92(12):1695-8.</citation>
    <PMID>18055995</PMID>
  </reference>
  <reference>
    <citation>Zaja F, Vianelli N, Volpetti S, Battista ML, Defina M, Palmieri S, Bocchia M, Medeot M, De Luca S, Ferrara F, Isola M, Baccarani M, Fanin R. Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2010 Oct;85(4):329-34. doi: 10.1111/j.1600-0609.2010.01486.x. Epub 2010 Jul 28.</citation>
    <PMID>20546023</PMID>
  </reference>
  <reference>
    <citation>Gómez-Almaguer D, Solano-Genesta M, Tarín-Arzaga L, Herrera-Garza JL, Cantú-Rodríguez OG, Gutiérrez-Aguirre CH, Jaime-Pérez JC. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. Blood. 2010 Dec 2;116(23):4783-5. doi: 10.1182/blood-2010-06-291831. Epub 2010 Sep 14.</citation>
    <PMID>20841509</PMID>
  </reference>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2011</study_first_submitted>
  <study_first_submitted_qc>April 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2011</study_first_posted>
  <last_update_submitted>April 29, 2011</last_update_submitted>
  <last_update_submitted_qc>April 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Wilma Barcellini, MD</name_title>
    <organization>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano</organization>
  </responsible_party>
  <keyword>Low dose rituximab</keyword>
  <keyword>WAIHA</keyword>
  <keyword>CHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemolysis</mesh_term>
    <mesh_term>Anemia, Hemolytic</mesh_term>
    <mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

